{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:33:06Z","timestamp":1793305986471,"version":"4.5.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.drudis.2026.104834","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:16:08Z","timestamp":1792077368000},"page":"104834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing a drug-development program is not the same as de-risking it"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8739-8087","authenticated-orcid":false,"given":"Mileidys","family":"Perez-Alea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104834_b0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41575-026-01249-x","article-title":"From researcher to CEO: closing the gap between discovery and delivery","volume":"23","author":"Mann","year":"2026","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.drudis.2026.104834_b0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrd4309","article-title":"Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework","volume":"13","author":"Cook","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2026.104834_b0015","unstructured":"Nonclinical evaluation for anticancer pharmaceuticals S9. International Council for Harmonisation Website. https:\/\/database.ich.org\/sites\/default\/files\/S9_Guideline.pdf. Published October 29, 2009. Accessed October 7, 2026."},{"key":"10.1016\/j.drudis.2026.104834_b0020","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2026.104834_b0025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.23.01868","article-title":"FDA approval summary: olaparib in combination with abiraterone for treatment of patients with BRCA-mutated metastatic castration-resistant prostate cancer","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104834_b0030","unstructured":"Lynparza: EPAR \u2013 product information. European Medicines Agency Website. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lynparza-epar-product-information_en.pdf. Published January 9, 2015. Updated February 19, 202Accessed October 7, 2026."},{"key":"10.1016\/j.drudis.2026.104834_b0035","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.2024027408","article-title":"Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study","volume":"146","author":"Zeidner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104834_b0040","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1182\/blood.2024027506","article-title":"The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy","volume":"146","author":"Daver","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2026.104834_b0045","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.3390\/cancers17091509","article-title":"Magrolimab therapy in conjunction with conventional chemotherapeutics slows disease progression in pediatric acute myeloid leukemia patient-derived xenograft models","volume":"17","author":"Kim","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2026.104834_b0050","unstructured":"Gap Fund: single-step support for medical product development. UK Research and Innovation Website. https:\/\/www.ukri.org\/opportunity\/gap-fund-single-step-support-for-medical-product-development\/. Published March 12, 2026. Updated July 16, 2026. Accessed October 7, 2026."}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626002394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:21:51Z","timestamp":1793305311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626002394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1359644626002394"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104834","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancing a drug-development program is not the same as de-risking it","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104834"}}